MX2011009824A - Derivados de pirimidina-diona fusionados como moduladores del trpa1. - Google Patents

Derivados de pirimidina-diona fusionados como moduladores del trpa1.

Info

Publication number
MX2011009824A
MX2011009824A MX2011009824A MX2011009824A MX2011009824A MX 2011009824 A MX2011009824 A MX 2011009824A MX 2011009824 A MX2011009824 A MX 2011009824A MX 2011009824 A MX2011009824 A MX 2011009824A MX 2011009824 A MX2011009824 A MX 2011009824A
Authority
MX
Mexico
Prior art keywords
tetrahydro
acetamide
dioxo
thiazol
pyrimidin
Prior art date
Application number
MX2011009824A
Other languages
English (en)
Spanish (es)
Inventor
Abraham Thomas
Neelima Khairatkar-Joshi
Sachin Sundarlal Chaudhari
Ashok Bhausaheb Kadam
Sachin Vasantrao Dhone
Sukeerthi Kumar
Indranil Mukhopadhyay
Nisha Parag Patil
Vishal Govindrao Deshmukh
Rajendra Prakash Chikhale
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of MX2011009824A publication Critical patent/MX2011009824A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2011009824A 2009-03-23 2010-03-17 Derivados de pirimidina-diona fusionados como moduladores del trpa1. MX2011009824A (es)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
IN665MU2009 2009-03-23
US17135509P 2009-04-21 2009-04-21
IN2211MU2009 2009-09-23
IN2212MU2009 2009-09-23
US25199409P 2009-10-15 2009-10-15
US25326309P 2009-10-20 2009-10-20
IN2892MU2009 2009-12-15
IN2891MU2009 2009-12-15
US29446310P 2010-01-12 2010-01-12
US30024110P 2010-02-01 2010-02-01
PCT/IB2010/000553 WO2010109287A1 (fr) 2009-03-23 2010-03-17 Dérivés de pyrimidinediones fusionnés utilisés comme modulateurs des récepteurs trpa1

Publications (1)

Publication Number Publication Date
MX2011009824A true MX2011009824A (es) 2012-01-25

Family

ID=42780198

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009824A MX2011009824A (es) 2009-03-23 2010-03-17 Derivados de pirimidina-diona fusionados como moduladores del trpa1.

Country Status (24)

Country Link
US (1) US9000159B2 (fr)
EP (2) EP2411393B1 (fr)
JP (1) JP5657638B2 (fr)
KR (1) KR20110132575A (fr)
CN (1) CN102361873B (fr)
AP (1) AP3280A (fr)
AU (1) AU2010227245B2 (fr)
BR (1) BRPI1013559A2 (fr)
CA (1) CA2756518A1 (fr)
CL (2) CL2011002315A1 (fr)
DK (1) DK2411393T3 (fr)
EA (1) EA023857B1 (fr)
ES (2) ES2456515T3 (fr)
HK (2) HK1166075A1 (fr)
IL (1) IL215178A (fr)
MX (1) MX2011009824A (fr)
PE (1) PE20120774A1 (fr)
PL (1) PL2411393T3 (fr)
PT (1) PT2411393E (fr)
SG (1) SG174402A1 (fr)
SI (1) SI2411393T1 (fr)
UA (1) UA108069C2 (fr)
WO (1) WO2010109287A1 (fr)
ZA (1) ZA201107648B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018724B1 (ru) 2006-08-07 2013-10-30 Айронвуд Фармасьютикалз, Инк. Соединения индола
UA108069C2 (uk) 2009-03-23 2015-03-25 Гленмарк Фармасьютікалс, С.А. Злиті піримідиндіонові похідні як модулятори trpa1
MX336549B (es) * 2010-12-20 2016-01-22 Glenmark Pharmaceuticals Sa Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1.
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
EP2520566A1 (fr) 2011-05-06 2012-11-07 Orion Corporation Nouveaux composés pharmaceutiques
MX2013014679A (es) 2011-06-13 2014-07-14 Glenmark Pharmaceuticals Sa Tratamiento de trastornos respiratorios usando antagonistas de trpa1.
CA2837429A1 (fr) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Composition pharmaceutique comprenant un antagoniste de trpa1 et un agoniste de beta-2
WO2012176105A1 (fr) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Composition pharmaceutique comprenant un antagoniste du trpa1 et un antagoniste du récepteur de leucotriènes
US20140148423A1 (en) 2011-07-25 2014-05-29 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and a steroid
TW201311690A (zh) 2011-08-09 2013-03-16 Hydra Biosciences Inc 抑制暫態受體電位離子通道ｔｒｐａ１
EP2787991A1 (fr) 2011-12-05 2014-10-15 Glenmark Pharmaceuticals S.A. Composition pharmaceutique comprenant un antagoniste de trpa1 et un agent anticholinergique
EP2805718B1 (fr) 2012-01-17 2018-04-04 EA Pharma Co., Ltd. Dérivé d'amine hétérocyclique et produit pharmaceutique le contenant
BR112014029155A2 (pt) 2012-06-08 2017-06-27 Glenmark Pharmaceuticals Sa amidas de compostos de 2-amino-4-ariltiazol e respectivos sais e processos de preparação
ES2624873T3 (es) 2012-10-01 2017-07-17 Orion Corporation Derivados de n-prop-2-inil carboxamida y su uso como antagonistas de trpa1
US9394308B2 (en) 2013-01-18 2016-07-19 Merck Sharp & Dohme Corp. Inhibiting the transient receptor potential A1 ion channel
JP2016537322A (ja) 2013-10-15 2016-12-01 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１アンタゴニスト及び鎮痛剤を含む医薬組成物
CA2927641C (fr) 2013-10-30 2023-03-14 Shanghai Hengrui Pharmaceutical Co., Ltd. Derives pyrazolopyrimidone ou pyrrolotriazone, leur procede de preparation, et applications pharmaceutiques associees
CN103755705B (zh) * 2014-02-17 2017-02-15 上海佰特因医药科技有限公司 一种天然产物四甲基尿酸的全合成方法
JP6667092B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体
WO2016042501A1 (fr) 2014-09-16 2016-03-24 Glenmark Pharmaceuticals S.A. Antagoniste de trpa1 permettant le traitement de la douleur associée à la douleur neuropathique diabétique
CN105001170A (zh) * 2015-07-13 2015-10-28 佛山市赛维斯医药科技有限公司 末端腈基取代的三氮唑亚砜类化合物、其制备方法及其用途
WO2017060488A1 (fr) 2015-10-09 2017-04-13 Almirall, S.A. Nouveaux antagonistes de trpa1
WO2017064068A1 (fr) 2015-10-14 2017-04-20 Almirall, S.A. Nouveaux antagonistes de trpa1
EP3660017A4 (fr) * 2017-07-28 2020-12-30 Jiangsu Hengrui Medicine Co., Ltd. Procédé de préparation d'un dérivé de pyrimidone hétéroaryle et intermédiaire d'un dérivé de pyrimidone hétéroaryle
CN109422749B (zh) * 2017-08-21 2023-01-24 重庆医药工业研究院有限责任公司 一种抑制单羧酸转运蛋白的嘧啶二酮衍生物
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
CN108558836A (zh) * 2018-05-14 2018-09-21 东南大学 一类具有双重作用机制的dpp-4抑制剂及其用途
WO2023096915A1 (fr) * 2021-11-24 2023-06-01 Slap Pharmaceuticals Llc Composés multicycliques
WO2023150592A2 (fr) * 2022-02-03 2023-08-10 D.E. Shaw Research, Llc Composés d'uracile n3-substitués utilisés en tant qu'inhibiteurs de trpa1
WO2023178035A1 (fr) * 2022-03-14 2023-09-21 Slap Pharmaceuticals Llc Composés multicycliques
CN114656473B (zh) * 2022-04-27 2023-09-29 成都施贝康生物医药科技有限公司 吡咯并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114656480B (zh) * 2022-04-27 2024-01-26 成都施贝康生物医药科技有限公司 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114656472B (zh) * 2022-04-27 2023-07-04 成都施贝康生物医药科技有限公司 吡唑并嘧啶类化合物、异构体或盐及其制备方法和用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248231A1 (de) 1972-10-02 1974-04-11 Basf Ag 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine
SE9701398D0 (sv) * 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
ES2193839B1 (es) * 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
AU2003253165A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
AU2003290066A1 (en) 2002-12-18 2004-07-09 Novartis Ag Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons
WO2005077959A1 (fr) * 2004-02-11 2005-08-25 Smithkline Beecham Corporation Agonistes de pth
US20070196866A1 (en) 2004-03-13 2007-08-23 Irm Llc Modulators of ion channel trpa1
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
WO2006083005A1 (fr) 2005-02-03 2006-08-10 Takeda Pharmaceutical Company Limited Dérivé de pyrimidine condensée et utilisation de celui-ci
US20060291462A1 (en) * 2005-06-28 2006-12-28 Utstarcom, Inc. Method and apparatus using multiple application cards to comprise multiple logical network entities
CN101384261B (zh) * 2005-12-22 2011-12-07 海德拉生物科学公司 治疗疼痛的组合物
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
WO2008094909A2 (fr) 2007-01-29 2008-08-07 Xenon Pharmaceuticals Inc. Composés de quinazolinone et de pyrimidinone fusionnés et leur utilisation dans le traitement de maladies ou d'affections induites par les canaux sodiques
AU2008268463B2 (en) * 2007-06-22 2015-03-05 Eli Lilly And Company Methods and compositions for treating disorders
WO2009158719A2 (fr) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Méthodes et compositions de traitement de troubles
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
EP2411395B1 (fr) 2009-03-23 2013-05-29 Glenmark Pharmaceuticals S.A. Dérivés de furopyrimidinedione à titre de modulateurs de trpa1
WO2010109328A1 (fr) 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Dérivés d'isothiazolo-pyrimidinedione utiles comme modulateurs de la trpa1
UA108069C2 (uk) 2009-03-23 2015-03-25 Гленмарк Фармасьютікалс, С.А. Злиті піримідиндіонові похідні як модулятори trpa1
AR076332A1 (es) 2009-04-21 2011-06-01 Boehringer Ingelheim Int Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones.
EP2442653A2 (fr) 2009-06-18 2012-04-25 Basf Se Mélanges fongicides
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
EP2311844A1 (fr) 2009-10-15 2011-04-20 Interquim, S.A. Composés d'ester d'acide benzoïque polymérique en silyl, utilisations, et compositions associées
AU2010308028A1 (en) 2009-10-15 2012-04-19 Pfizer Inc. Pyrrolo[2,3-d] pyrimidine compounds
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
WO2012006953A1 (fr) 2010-07-13 2012-01-19 Novartis Ag Dérivés de l'oxazine et leur utilisation dans le traitement de troubles neurologiques

Also Published As

Publication number Publication date
HK1194742A1 (en) 2014-10-24
SI2411393T1 (sl) 2014-03-31
HK1166075A1 (en) 2012-10-19
IL215178A0 (en) 2011-12-29
ES2551085T3 (es) 2015-11-16
BRPI1013559A2 (pt) 2016-04-12
CL2014001447A1 (es) 2014-10-17
US20140128603A1 (en) 2014-05-08
UA108069C2 (uk) 2015-03-25
CA2756518A1 (fr) 2010-09-30
AU2010227245A2 (en) 2011-10-27
AP2011005887A0 (en) 2011-10-31
KR20110132575A (ko) 2011-12-08
JP5657638B2 (ja) 2015-01-21
US9000159B2 (en) 2015-04-07
DK2411393T3 (da) 2014-04-07
AU2010227245B2 (en) 2015-09-10
PT2411393E (pt) 2014-02-21
EA023857B1 (ru) 2016-07-29
CL2011002315A1 (es) 2012-04-09
AP3280A (en) 2015-05-31
EP2708538B1 (fr) 2015-08-12
CN102361873B (zh) 2014-07-09
JP2012521401A (ja) 2012-09-13
ES2456515T3 (es) 2014-04-22
PE20120774A1 (es) 2012-06-27
EP2411393A1 (fr) 2012-02-01
EP2411393A4 (fr) 2012-08-01
EA201190143A1 (ru) 2012-04-30
PL2411393T3 (pl) 2014-06-30
SG174402A1 (en) 2011-10-28
IL215178A (en) 2015-01-29
ZA201107648B (en) 2012-07-25
EP2411393B1 (fr) 2014-01-22
WO2010109287A1 (fr) 2010-09-30
EP2708538A1 (fr) 2014-03-19
AU2010227245A1 (en) 2011-09-22
CN102361873A (zh) 2012-02-22

Similar Documents

Publication Publication Date Title
MX2011009824A (es) Derivados de pirimidina-diona fusionados como moduladores del trpa1.
AU735401B2 (en) Substituted 6,5-hetero-bicyclic derivatives
JP6432624B2 (ja) ３環性ヘテロ環化合物及びｊａｋ阻害剤
CA2800541C (fr) Activateurs de guanylate cyclase soluble
AU2004235907B2 (en) Fused pyrimidine derivatives with CRF activity
MX2011009822A (es) Derivados de tienopirimidinadiona como moduladores del trpa1.
US20020151713A1 (en) Substituted 6,5-hetero-bicyclic derivatives
JP2012521401A5 (fr)
JP6285013B2 (ja) ３，５−（非）置換−１Ｈ−ピロロ［２，３−ｂ］ピリジン、１Ｈ−ピラゾロ［３，４−ｂ］ピリジン、及び５Ｈ−ピロロ［２，３−ｂ］ピラジン、ＩＴＫ及びＪＡＫ３キナーゼの阻害剤
RU2011116928A (ru) Гетероциклические ингибиторы jак киназы
CA2600832A1 (fr) Inhibiteurs de l'integrase du vih
AU2004290626A1 (en) Bicyclic pyrimidin-4-(3H)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (VR1)
WO2010125469A1 (fr) Composés hétérocycliques fusionnés à une pyrimidine dione en tant que modulateurs de trpa1
CA2440760C (fr) Pyrazolopyrimidines et thiazolopyrimidines substituees
WO2011114184A1 (fr) Amides de composés hétérocycliques à titre d'inhibiteurs de trpa1
MX2011009821A (es) Derivados de isotiazolo pirimidinadiona como moduladores del trpa1.
Hassan et al. Synthesis and Anticancer Evaluation of Some Novel Thiophene, Thieno [3, 2‐d] pyrimidine, Thieno [3, 2‐b] pyridine, and Thieno [3, 2‐e][1, 4] oxazepine Derivatives Containing Benzothiazole Moiety
Gupta et al. A review on the synthesis and therapeutic potential of pyrimidine derivatives
CN114656472B (zh) 吡唑并嘧啶类化合物、异构体或盐及其制备方法和用途
CZ20032339A3 (cs) Farmaceutický prostředek obsahující parazolo [4,3-d]pyrimidiny a nitráty nebo thienopyrimidiny a nitráty
CN114656480B (zh) 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114656473B (zh) 吡咯并嘧啶类化合物、异构体或盐及其制备方法和用途
KR20030076633A (ko) 트리아조로퀴나졸린 및 피라졸로 트리아조로피리미딘유도체, 의약조성물,아데노신 에이3 수용체 친화제,안압저하제, 녹내장의 예방 및 치료를 위한 제제 및안압저하 방법
CN114671876B (zh) 新型茶碱类化合物、异构体或盐及其制备方法和用途
Abdel-Megid et al. Synthesis and Mollucicidal Activity of Some New Bicyclic and Polycyclic Pyrimidine Derivatives